Abstract
Histone acetylation is a key regulatory factor for gene expression in cells. Modulation of histone acetylation by targeting of histone acetyltransferases (HATs) effectively alters many gene expression profiles and synaptic plasticity in the brain. However, the role of HATs on l-DOPA-induced dyskinesia of Parkinson’s disease (PD) has not been reported. Our aim was to determine whether HAT inhibitors such as anacardic acid, garcinol, and curcumin from natural plants reduce severity of l-DOPA-induced dyskinesia using a unilaterally 6-hydroxydopamine (6-OHDA)-lesioned PD mouse model. Anacardic acid 2 mg/kg, garcinol 5 mg/kg, or curcumin 100 mg/kg co-treatment with l-DOPA significantly reduced the axial, limb, and orofacial (ALO) score indicating less dyskinesia with administration of HAT inhibitors in 6-OHDA-lesioned mice. Additionally, l-DOPA’s efficacy was not altered by the compounds in the early stage of treatment. The expression levels of c-Fos, Fra-2, and Arc were effectively decreased by administration of HAT inhibitors in the ipsilateral striatum. Our findings indicate that HAT inhibitor co-treatment with l-DOPA may have therapeutic potential for management of l-DOPA-induced dyskinesia in patients with PD.
Original language | English |
---|---|
Pages (from-to) | 1319-1331 |
Number of pages | 13 |
Journal | Journal of Neural Transmission |
Volume | 125 |
Issue number | 9 |
DOIs | |
State | Published - 1 Sep 2018 |
Bibliographical note
Funding Information:Acknowledgements This work was supported by the KRIBB Research Initiative Program of the Republic of Korea, by the Development of Platform Technology for Innovative Medical Measurements Program (No. KRISS-2018-GP2018-0018) from the Korea Research Institute of Standards and Science and by the National Research Foundation of Korea grant funded by the Korea government (MSIT) (No. 2018R1C1B6005079).
Publisher Copyright:
© 2018, Springer-Verlag GmbH Austria, part of Springer Nature.
Keywords
- 6-Hydroxydopamine
- Anacardic acid
- Curcumin
- Garcinol
- HAT inhibitor
- l-DOPA-induced dyskinesia